- Phase 3 since 20 Apr 2023: CSPC Pharmaceutical Group Limited’s first study of it at that phase, by the day it was submitted to ClinicalTrials.gov.
- Next primary completion: 16 Dec 2026, the registry's estimate, of NCT06747338 (phase 3) — when its main measure’s data collection ends, not when results are announced.study pageClinicalTrials.gov ↗
- 8 live studies are past an estimated primary completion the registry has not updated.
- One program: HB1801Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: BH011Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: XRP6976Judged by our rule (version d2907d7): the same study entry names both · 2026-11-14
- One program: CKD810Judged by our rule (version d2907d7): FDA's UNII names them as one substance · 2026-11-14
- Evidence: FDA UNII 699121PHCA (DOCETAXEL ANHYDROUS)FDA record ↗
- Kept apart: another drug record (INT012253)Judged by our rule (version d2907d7): two different drugs in our concepts · 2026-11-14
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Jazz Pharmaceuticals leads of it also tests zanidatamab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Ferring Pharmaceuticals leads of it also tests nadofaragene firadenovec.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies AstraZeneca leads of it in the last 24 months also tests sonesitatug vedotin, trastuzumab deruxtecan, Leucovorin.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies CatalYm GmbH leads of it also tests visugromab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Johnson & Johnson leads of it also tests amivantamab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 5 studies Sichuan Biokin Pharmaceutical Co., Ltd. leads of it also tests izalontamab brengitecan, Anti-HER2 Antibody-drug Conjugate BL-M07D1, Irinotecan.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies R-Pharm leads of it also tests RPH-051.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Akeso leads of it in the last 24 months also tests ivonescimab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 5 studies Bristol-Myers Squibb leads of it also tests Nivolumab, rucaparib, Anti-CTLA4 Monoclonal Antibody BMS-986218.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies iOnctura leads of it also tests roginolisib.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies AbbVie leads of it also tests livmoniplimab, budigalimab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Arcus Biosciences, Inc. leads of it also tests AB928.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies BeOne Medicines leads of it also tests sitravatinib, tislelizumab, Irinotecan.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Qilu Pharmaceutical Co., Ltd. leads of it also tests QLM2011.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Jina Pharmaceuticals Inc. leads of it also tests Nanosomal Docetaxel Lipid Suspension.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies NeoTX Therapeutics Ltd. leads of it also tests naptumomab estafenatox.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 2 studies Boehringer Ingelheim leads of it also tests nintedanib.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Zydus Lifesciences Limited leads of it also tests eflapegrastim.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Gilead Sciences leads of it also tests FLT3 Agonist-Fc Fusion Protein GS-3583, zimberelimab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Sinocelltech Group Limited leads of it also tests SCT-I10.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Jiangsu HengRui Medicine Co., Ltd. leads of it also tests pyrotinib.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Cellxpert Biotechnology Corp. leads of it also tests phosphomannopentaose sulfate.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Lumos Pharma, Inc. leads of it also tests indoximod.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies HUTCHMED leads of it also tests savolitinib.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Daiichi Sankyo leads of it also tests AC480IV.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Astellas Pharma Inc leads of it also tests sepantronium.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 2 studies Infinity Pharmaceuticals, Inc. leads of it also tests tanespimycin.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies COSCIENS Biopharma Inc. leads of it also tests perifosine.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Genta Incorporated leads of it also tests oblimersen.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Introgen Therapeutics leads of it also tests advexin.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 2 studies Arog Pharmaceuticals, Inc. leads of it also tests crenolanib, Axitinib.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Agennix leads of it also tests satraplatin.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Proacta, Incorporated leads of it also tests PR-104.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies NeuTec Pharma leads of it also tests efungumab.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Cytogen Corporation leads of it also tests samarium Sm-153 lexidronam.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 2 studies Point Therapeutics leads of it also tests talabostat mesylate.
- Given alongside, not the company's programJudged by our rule (version d2907d7): an approved drug many companies test, given beside the company's own in each of its studies · 2026-11-14Approved and tested by 64 companies; each of the 1 studies Titan Pharmaceuticals leads of it also tests AN-9.
|